当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2015年
5期
159-160
,共2页
心力衰竭%富马酸比索洛尔%心舒1号%β1受体阻滞剂
心力衰竭%富馬痠比索洛爾%心舒1號%β1受體阻滯劑
심력쇠갈%부마산비색락이%심서1호%β1수체조체제
Cardiac failure%Bisoprolol fumarate%Xin shu1%Theβ1 receptor blockers
目的：评价联合应用富马酸比索洛尔和心舒1号治疗心力衰竭的疗效。方法选择慢性心衰患者88例，随机均分为治疗组和对照组（n=44）；对照组常规抗心衰治疗：低盐饮食，注意休息，适当进行有氧运动，应用利尿剂、地高辛、硝酸酯类药物，治疗组在上述治疗基础上加用富马酸比索洛尔和心舒1号。比较2组总体疗效。治疗前和治疗后4个月分别做超声心动图，比较2组LVEDD、LVEF、NT-proBNP的变化。结果治疗组总有效率为90.0%，对照组总有效率为59.1%，2组总有效率的差异有统计学意义（P<0.05）。治疗组治疗后LVEDD为（60.4±6.5）mm，治疗前为（65.7±7.2）mm；对照组治疗后LVEDD为（63.8±7.4）mm，治疗前为（66.1±75.0）mm；2组治疗后差异有统计学意义（P<0.05）。治疗组治疗后LVEF为（46.2±11.9）%，治疗前为（29.1±11.3）%；对照组治疗后为（42.4±13.2）%，治疗前为（29.3±11.0）%；2组治疗后差异有统计学意义（P<0.05）。治疗组治疗后NT-proBNP为（302.0±36.2）pg/mL，治疗前为（1895.0±20.6）pg/mL；对照组治疗后为（612.0±45.2）pg/mL，治疗前为（1886.0±23.4）pg/mL；2组治疗后差异有统计学意义（P<0.05）。结论在对照组的基础上联合应用富马酸比索洛尔和心舒1号可以降低LVEDD，显著提升LVEF，使NT-proBNP明显下降，有益于慢性心力衰竭的治疗。
目的：評價聯閤應用富馬痠比索洛爾和心舒1號治療心力衰竭的療效。方法選擇慢性心衰患者88例，隨機均分為治療組和對照組（n=44）；對照組常規抗心衰治療：低鹽飲食，註意休息，適噹進行有氧運動，應用利尿劑、地高辛、硝痠酯類藥物，治療組在上述治療基礎上加用富馬痠比索洛爾和心舒1號。比較2組總體療效。治療前和治療後4箇月分彆做超聲心動圖，比較2組LVEDD、LVEF、NT-proBNP的變化。結果治療組總有效率為90.0%，對照組總有效率為59.1%，2組總有效率的差異有統計學意義（P<0.05）。治療組治療後LVEDD為（60.4±6.5）mm，治療前為（65.7±7.2）mm；對照組治療後LVEDD為（63.8±7.4）mm，治療前為（66.1±75.0）mm；2組治療後差異有統計學意義（P<0.05）。治療組治療後LVEF為（46.2±11.9）%，治療前為（29.1±11.3）%；對照組治療後為（42.4±13.2）%，治療前為（29.3±11.0）%；2組治療後差異有統計學意義（P<0.05）。治療組治療後NT-proBNP為（302.0±36.2）pg/mL，治療前為（1895.0±20.6）pg/mL；對照組治療後為（612.0±45.2）pg/mL，治療前為（1886.0±23.4）pg/mL；2組治療後差異有統計學意義（P<0.05）。結論在對照組的基礎上聯閤應用富馬痠比索洛爾和心舒1號可以降低LVEDD，顯著提升LVEF，使NT-proBNP明顯下降，有益于慢性心力衰竭的治療。
목적：평개연합응용부마산비색락이화심서1호치료심력쇠갈적료효。방법선택만성심쇠환자88례，수궤균분위치료조화대조조（n=44）；대조조상규항심쇠치료：저염음식，주의휴식，괄당진행유양운동，응용이뇨제、지고신、초산지류약물，치료조재상술치료기출상가용부마산비색락이화심서1호。비교2조총체료효。치료전화치료후4개월분별주초성심동도，비교2조LVEDD、LVEF、NT-proBNP적변화。결과치료조총유효솔위90.0%，대조조총유효솔위59.1%，2조총유효솔적차이유통계학의의（P<0.05）。치료조치료후LVEDD위（60.4±6.5）mm，치료전위（65.7±7.2）mm；대조조치료후LVEDD위（63.8±7.4）mm，치료전위（66.1±75.0）mm；2조치료후차이유통계학의의（P<0.05）。치료조치료후LVEF위（46.2±11.9）%，치료전위（29.1±11.3）%；대조조치료후위（42.4±13.2）%，치료전위（29.3±11.0）%；2조치료후차이유통계학의의（P<0.05）。치료조치료후NT-proBNP위（302.0±36.2）pg/mL，치료전위（1895.0±20.6）pg/mL；대조조치료후위（612.0±45.2）pg/mL，치료전위（1886.0±23.4）pg/mL；2조치료후차이유통계학의의（P<0.05）。결론재대조조적기출상연합응용부마산비색락이화심서1호가이강저LVEDD，현저제승LVEF，사NT-proBNP명현하강，유익우만성심력쇠갈적치료。
Objective Evaluation of the efficacy of the combination of bisoprolol fumarate and diastolic heart failure treatment on the 1st. Methods 88 chronic heart failure patients were randomLy divided into treatment group and control group (n=44); the control group conventional therapy: a low-salt diet, adequate rest, proper aerobic exercise, diuretics, digoxin, nitrates, the treatment group in the above treatment based on the use of bisoprolol fumarate and diastolic on the 1st. The overall effect of the two groups. Before treatment and after 4 months were done echocardiography were compared LVEDD, changes in LVEF, NT-proBNP in.Results The total effective rate was 90.0% in the control group, the total effective rate was 59.1%, the total difference between the two groups was statistically significant efficiency (P<0.05). After treatment LVEDD was (60.4 ± 6.5)mm, was (65.7 ± 7.2)mm before treatment; control group after treatment LVEDD was (63.8 ± 7.4)mm, was (66.1 ± 75.0)mm before treatment, significant difference was statistically significant (P<0.05). After treatment, LVEF was (46.2 ± 11.9)%, before treatment is (29.1 ± 11.3)%; control group after treatment was (42.4 ± 13.2)%, before treatment was (29.3 ± 11.0)%, a significant difference was statistically significant (P<0.05). Treatment group after treatment NT-proBNP was (302.0 ± 36.2)pg / mL, before treatment was (1895.0 ± 20.6)pg/mL; the control group was (612.0 ± 45.2)pg/mL, before treatment was (1886 ± 23.4)pg/mL, significantly different, there was statistically significant (P<0.05).Conclusion In the control group on the basis of the combination of bisoprolol fumarate and diastolic reduces the 1st LVEDD, significantly improved LVEF, so that NT-proBNP decreased, beneficial treatment of chronic heart failure.
